In the past ten years since Iowa legalized cannabis for medical purposes, the state’s program has remained among the most stringent in the U.S. Initially launched in 2014 to allow cannabis oil for specific health conditions, the program has since broadened slightly under the Iowa Medical Cannabidiol program, yet still imposes tight restrictions limiting its effectiveness and accessibility.

As noted by Morgan Fox of NORML, Iowa’s medical cannabis program is considered “incredibly limited” compared to the comprehensive programs in 37 states and Washington, D.C. For instance, Iowa restricts THC purchases to 4.5 grams every 90 days, with waivers possible, limiting treatment options for patients who may benefit from higher doses.

Despite having 18,000 active patient cardholders and generating $13.6 million in sales last year, advocates argue that the program’s stringent nature prevents many Iowans from experiencing the full therapeutic potential of cannabis. The state continues to debate potential expansions, but significant changes appear unlikely in the near future, leaving Iowa lagging behind as other states advance more inclusive policies.

Read more about the ongoing challenges and comparisons with other states in the original article from The Des Moines Register.